Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$49 Mln
P/E Ratio
--
P/B Ratio
1.1
Industry P/E
--
Debt to Equity
0.34
ROE
-0.39 %
ROCE
-31.65 %
Div. Yield
0 %
Book Value
1.1
EPS
-0.51
CFO
€-8.62 Mln
EBITDA
€-27.25 Mln
Net Profit
€-22.52 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
EDAP TMS S.A. - ADR
| -37.56 | -38.67 | -37.27 | -81.10 | -42.48 | -7.97 | -8.07 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
EDAP TMS S.A. - ADR
| -57.85 | -50.47 | 77.96 | 15.86 | 16.70 | 139.46 | -35.39 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally.... The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France. Address: Parc dActivites la Poudrette-Lamartine, Lyon, France, 69120 Read more
Executive Chairman
Mr. Marc Oczachowski
Executive Chairman
Mr. Marc Oczachowski
Headquarters
Lyon
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of EDAP TMS SA - ADR stood at $ 86 Mln as on 31-Dec-24
The share price of EDAP TMS SA - ADR is $1.38 (NASDAQ) as of 17-Apr-2025 16:00 EDT. EDAP TMS SA - ADR has given a return of -42.48% in the last 3 years.
EDAP TMS SA - ADR has a market capitalisation of $ 49 Mln as on 17-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of EDAP TMS SA - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the EDAP TMS SA - ADR and enter the required number of quantities and click on buy to purchase the shares of EDAP TMS SA - ADR.
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France. Address: Parc dActivites la Poudrette-Lamartine, Lyon, France, 69120
The CEO & director of Mr. Marc Oczachowski. is EDAP TMS SA - ADR, and CFO & Sr. VP is Mr. Marc Oczachowski.
There is no promoter pledging in EDAP TMS SA - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| EDAP TMS S.A. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-38.88
|
|
Operating margin(%)
|
-28.84
|
|
Net Margin(%)
|
-29.66
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of EDAP TMS SA - ADR was $0 Mln.
$0.07
(
